Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Depreciation and Depletion (2020 - 2023)

Rein Therapeutics (RNTX) has disclosed Depreciation and Depletion for 4 consecutive years, with $12000.0 as the latest value for Q4 2023.

  • Quarterly Depreciation and Depletion fell 90.4% to $12000.0 in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $49000.0 through Dec 2023, down 71.01% year-over-year, with the annual reading at $49000.0 for FY2023, 71.01% down from the prior year.
  • Depreciation and Depletion for Q4 2023 was $12000.0 at Rein Therapeutics, roughly flat from $12000.0 in the prior quarter.
  • The five-year high for Depreciation and Depletion was $125000.0 in Q4 2022, with the low at $2000.0 in Q1 2021.
  • Average Depreciation and Depletion over 4 years is $32312.5, with a median of $14000.0 recorded in 2020.
  • Peak annual rise in Depreciation and Depletion hit 960.0% in 2021, while the deepest fall reached 97.14% in 2021.
  • Over 4 years, Depreciation and Depletion stood at $10000.0 in 2020, then skyrocketed by 960.0% to $106000.0 in 2021, then increased by 17.92% to $125000.0 in 2022, then tumbled by 90.4% to $12000.0 in 2023.
  • According to Business Quant data, Depreciation and Depletion over the past three periods came in at $12000.0, $12000.0, and $12000.0 for Q4 2023, Q3 2023, and Q2 2023 respectively.